ReviewCureus2023
Advances in Anti-obesity Pharmacotherapy: Current Treatments, Emerging Therapies, and Challenges.
Review in Cureus, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 2 syntheses or guidelines pooled it, 36 citations in OpenAlex.
- Joint TOS/OMA/OAC Expert Guidance Statement on the Pharmacological Management of United States Adults With Overweight or Obesity Using the GRADE Approach.Obesity (Silver Spring, Md.) · 2026Guideline
- Anti-Obesity Effects of Sulphated Polysaccharides Derived from Marine Macro Algae or Seaweeds: A Systematic Review and Meta-Analysis.Marine drugs · 2024Pooled it
- Beyond GLP-1 Agonists: Plant-Derived Bioactive Compounds as Adjunctive Strategies for Obesity Management.Nutrients · 2026Review
- Joint TOS/OMA/OAC expert guidance statement on the pharmacological management of United States adults with overweight or obesity using the GRADE approach.Obesity pillars · 2026Article
- Natural product-based interventions for thyroid disorders: mechanisms and applications.Naunyn-Schmiedeberg's archives of pharmacology · 2026Review
- A Narrative Review of Weight Management Strategies: From Lifestyle Interventions to Emerging Pharmacotherapies.Journal of obesity · 2026Review
- The Genetic Blueprint of Obesity: From Pathogenesis to Novel Therapies.Obesity reviews : an official journal of the International Association for the Study of Obesity · 2025Review
- GLP-1 receptor agonists: emerging therapeutic potential in psoriasis management - current evidence and future outlook.European journal of clinical pharmacology · 2025Review
- Article
- Liraglutide Reduces Liver Steatosis and Improves Metabolic Indices in Obese Patients Without Diabetes: A 3-Month Prospective Study.International journal of molecular sciences · 2025Article
- The Mechanisms of Chronic Inflammation in Obesity and Potential Therapeutic Strategies: A Narrative Review.Current issues in molecular biology · 2025Review
- Lipid-based nano-carriers for the delivery of anti-obesity natural compounds: advances in targeted delivery and precision therapeutics.Journal of nanobiotechnology · 2025Review
- Role of pancreatic lipase inhibition in obesity treatment: mechanisms and challenges towards current insights and future directions.International journal of obesity (2005) · 2025Review
- Alpha-melanocyte-stimulating hormone contributes to an anti-inflammatory response to lipopolysaccharide.Molecular metabolism · 2024Article
- Beyond Weight Loss: Evaluating Cardiovascular Advantages of GLP-1 Receptor Agonists.American journal of cardiovascular drugs : drugs, devices, and other interventions · 2024Article
- Trends and characteristics of the metabolically healthy obese phenotype in an Arab population.Frontiers in public health · 2024Article
- Controlled Quercetin Release by Fluorescent Mesoporous Nanocarriers for Effective Anti-Adipogenesis.International journal of nanomedicine · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Obesity is a major public health concern linked to health risks such as hypertension, hyperlipidemia, type 2 diabetes mellitus (T2DM), stroke, metabolic syndrome, asthma, and cancer. It is among the leading causes of morbidity and mortality worldwide caused by an unhealthy diet and lack of physical activity, but genetic or hormonal factors may also contribute. Over a third of adults in the United States are obese. Pharmacological agents have been designed to reduce weight gain caused by excessive calorie intake and low physical activity. They work by inhibiting the absorption of dietary fat or stimulating the secretion of satiety hormones. These drugs include lipase inhibitors and glucagon-like peptide 1 (GLP-1) receptor agonists. However, the current weight-loss strategies do not effectively treat genetic-related diseases, such as generalized lipodystrophy, Bardet-Biedl syndrome, and proopiomelanocortin (POMC) deficiency. Emerging therapies for these gene mutations have been developed targeting leptin and melanocortin-4 receptors (MC4Rs), restoring the normal function of leptin or melanocortin-4 receptors regulating energy balance and appetite. Leptin analogs and MC4R agonists are novel therapies that target genetic or hormonal causes of obesity. This article provides a comprehensive review of anti-obesity medications (AOMs). In this review, we discuss the clinical trials, efficacy, United States FDA-approved indication, contraindications, and serious side effects of different classes of drugs, including lipase inhibitors, GLP-1 agonists, leptin analogs, and MC4R agonists.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.